Title: Computational Systems Biology of Cancer
1(I)
Computational Systems Biology of Cancer
2Bud Mishra
- Professor of Computer Science, Mathematics and
Cell Biology -
- Courant Institute, NYU School of Medicine, Tata
Institute of Fundamental Research, and Mt. Sinai
School of Medicine
3(No Transcript)
4War on Cancer
- Reports that say that something hasn't happened
are always interesting to me, because as we know,
there are known knowns there are things we know
we know. We also know there are known unknowns
that is to say we know there are some things we
do not know. But there are also unknown unknowns
the ones we don't know we don't know. - US Secretary of Defense, Mr. Donald Rumsfeld,
Quoted completely out of context.
5Introduction Cancer and Genomics
- What we know what we do not
- Cancer is a disease of the genome.
6Outline
- Genomics
- Genome Modification Repair
- Segmental Duplications Models
7Genomics
- Genome
- Hereditary information of an organism is encoded
in its DNA and enclosed in a cell (unless it is a
virus). All the information contained in the DNA
of a single organism is its genome. - DNA molecule can be thought of as a very long
sequence of nucleotides or bases - S A, T, C, G
8Complementarity
- DNA is a double-stranded polymer and should be
thought of as a pair of sequences over S. - However, there is a relation of complementarity
between the two sequences - A , T, C , G
9DNA Structure.
- The four nitrogenous bases of DNA are arranged
along the sugar- phosphate backbone in a
particular order (the DNA sequence), encoding all
genetic instructions for an organism. - Adenine (A) pairs with thymine (T), while
cytosine (C) pairs with guanine (G). - The two DNA strands are held together by weak
bonds between the bases.
10 Structure and Components
- Complementary base pairs
- (A-T and C-G)
- Cytosine and thymine are smaller (lighter)
molecules, called pyrimidines - Guanine and adenine are bigger (bulkier)
molecules, called purines. - Adenine and thymine allow only for double
hydrogen bonding, while cytosine and guanine
allow for triple hydrogen bonding.
11Inert Rigid
- Thus the chemical (hydrogen bonding) and the
mechanical (purine to pyrimidine) constraints on
the pairing lead to the complementarity and makes
the double stranded DNA both chemically inert and
mechanically quite rigid and stable.
12The Central Dogma
- The central dogma(due to Francis Crick in 1958)
states that these information flows are all
unidirectional - The central dogma states that once information'
has passed into protein it cannot get out again.
13The Central Dogma
- The transfer of information from nucleic acid
to nucleic acid, or from nucleic acid to protein,
may be possible, but transfer from protein to
protein, or from protein to nucleic acid is
impossible. Information means here the precise
determination of sequence, either of bases in the
nucleic acid or of amino acid residues in the
protein.
14The New Synthesis
15Cancer Initiation and Progression
Mutations, Translocations, Amplifications,
Deletions Epigenomics (Hyper Hypo-Methylation) A
lternate Splicing
Cancer Initiation and Progression
Proliferation, Motility, Immortality, Metastasis,
Signaling
16Multi-step Nature of Cancer
- Cancer is a stepwise process, typically requiring
accumulation of mutations in a number of genes. - 6-7 independent mutations typically occur over
several decades - Conversion of proto-oncogenes to oncogenes
- Inactivation of tumor suppressor gene
17Amplifications Deletions
Mutation in a TSG
Epigenomics
Conversion of a Proto-Oncogene
Deletion of a TSG
Deletion of a TSG
18P53 Gene (TSG)
19The Cancer Genome Atlas
- Obtain a comprehensive description of the genetic
basis of human cancer. - Identify and characterize all the sites of
genomic alteration associated at significant
frequency with all major types of cancers.
20The Cancer Genome Atlas
- Increase the effectiveness of research to
understand - tumor initiation and progression,
- susceptibility to carcinogensis,
- development of cancer therapeutics,
- approaches for early detection of tumors
- the design of clinical trials.
21Specific Goals
- Identify all genomic alterations significantly
associated with all major cancer types. - Such knowledge will propel work by thousands of
investigators in cancer biology, epidemiology,
diagnostics and therapeutics.
22To Achieve this goal
- Create large collection of appropriate,
clinically annotated samples from all major types
of cancer and
- Characterize each sample in terms of
- All regions of genomic loss or amplification,
- All mutations in the coding regions of all human
genes, - All chromosomal rearrangements,
- All regions of aberrant methylation, and
- Complete gene expression profile, as well as
other appropriate technologies.
23Biomedical Rationale
- Cancer is a heterogeneous collection of
heterogeneous diseases. - For example, prostate cancer can be an indolent
disease remaining dormant throughout life or an
aggressive disease leading to death. - However, we have no clear understanding of why
such tumors differ.
24Biomedical Rationale
- Cancer is fundamentally a disease of genomic
alteration. - Cancer cells typically carry many genomic
alterations that confer on tumors their
distinctive abilities (such as the capacity to
proliferate and metastasize, ignoring the normal
signals that block cellular growth and migration)
and liabilities (such as unique dependence on
certain cellular pathways, which potentially
render them sensitive to certain treatments that
spare normal cells).
25History
- 1960s
- The genetic basis of cancer was clear from
cytogenetic studies that showed consistent
translocations associated with specific cancers
(notably the so-called Philadelphia chromosome in
chronic myelogenous leukemia). - 1970s
- Recognize specific cancer-causing mutations
through recombinant DNA revolution of the 1970s. - The identification of the first vertebrate and
human oncogenes and the first tumor suppressor
genes, - These discoveries have elucidated the cellular
pathways governing processes such as cell-cycle
progression, cell-death control, signal
transduction, cell migration, protein
translation, protein degradation and
transcription. - For no human cancer do we have a comprehensive
understanding of the events required.
26Scientific Foundation for a Human Cancer Genome
Project
- Gene resequencing.
- Specific gene classes (such as kinases and
phosphatases) in particular cancer types. - Epigenetic changes.
- Loss of function of tumor suppressor genes by
epigenetic modification of the genome such as
DNA methylation and histone modification. - Genomic loss and amplification.
- Consistent association with genomic loss or
amplification in many specific regions,
indicating that these regions harbor key cancer
associated genes
- Chromosome rearrangements.
- Activate kinase pathways through fusion proteins
or inactivating differentiation programs through
gene disruption. - Hematological malignancies a single
stereotypical translocation in some diseases
(such as CML) and as many as 20 important
translocations in others (such as AML). - Adult solid tumors have not been as well
characterized, in part owing to technical
hurdles.
27Human Genome Structure
28EBD
- J.B.S. Haldane (1932)
- A redundant duplicate of a gene may acquire
divergent mutations and eventually emerge as a
new gene. - Susumu Ohno (1970)
- Natural selection merely modified, while
redundancy created.
29Evolution by Duplication
30Human Condition
31Mer-scape
- Overlapping words of different sizes are analyzed
for their frequencies along the whole human
genome - Red 24-mers,
- Green 21-mers
- Blue18 mers
- Gray15 mers
- To the very left is a ubiquitous human
transposon Alu. The high frequency is indicative
of its repetitive nature. - To the very right is the beginning of a gene. The
low frequency is indicative of its uniqueness in
the whole genome.
32Doublet Repeats
- Serendipitous discovery of a new uncataloged
class of short duplicate sequences doublet
repeats. - almost always lt 100 bp
- (Top) . The distance between the two loci of a
doublet is plotted versus the chromosomal
position of the first locus. - (Bottom) Distribution of doublets (black) and
segmental duplications (red) across human
chromosome 2
33Segmental Duplications
- 3.5 5 of the human genome is found to contain
- segmental duplications, with length gt 5 or 1kb,
identity gt 90. - These duplications are estimated to have emerged
about 40Mya under neutral assumption. - The duplications are mostly interspersed
(non-tandem), and happen both inter- and
intra-chromosomally.
Human
From Bailey, et al. 2002
34The Model
35The Mathematical Model
0 d lt e
e d lt 2e
(k-1)e d lt ke
h1 proportion of duplications by repeat
recombination h1 proportion of
duplications by recombination of the specific
repeat h1- - proportion of duplications
by recombination of other repeats h0 proportion
of duplications by other repeat-unrelated
mechanism h0 proportion of h0 with
common specific repeat in the flanking regions
h0- proportion of h0 with no common
specific repeat in the flanking regions
h0- - proportion of h0 with no specific repeat
in the flanking regions
a mutation rate in duplicated sequences ß
insertion rate of the specific repeat ?
mutation rate in the specific repeat d
divergence level of duplications e divergence
interval of duplications.
36Model Fitting
- The model parameters (aAlu, ßAlu, ?Alu, aL1, ßL1,
?L1) are estimated from the reported mutation and
insertion rates in the literature. - The relative strengths of the alternative
hypotheses can be estimated by model fitting to
the real data. - h1Alu 0.76 h1Alu 0.3 h1L1 0.76 h1 L1
0.35.
37Polyas Urn
38Repetitive Random Eccentric GOD
- Genome Organizing Devices (GOD)
- Polyas Urn Model
- Fs functions deciding probability distributions
39DNA polymerase stuttering(replication slippage)
normal replication
DNA polymerase
normal replication
polymerase pausing and dissociation
polymerase pausing and dissociation
3 realignment and polymerase reloading
3 realignment and polymerase reloading
40Transposons causes deletions and duplications
- Transposon actions in
- genomic DNA
Donor DNA
transposon
DNA intermediates
Target DNA
Transposase cuts in target DNA
transposon
IS
IS
Transposon looping out
Transposon inserted
Transposon deleted
DNA is repaired-resulting in a duplication of the
transposon and target site
41DNA mismatch repair mechanism prevents
duplications and deletions
Mismatch recognition on daughter strand
Degradation of the mismatched daughter strand in
the a-loop
DNA a-loop formation by translocation through the
proteins
Refilling the gap by DNA polymerase
Corrected daughter strand
DNA polymerase
42Graph Model
A. Deletion With probability p0
- Graph description
- G V, E, G is a directed multi-graph
- V ? Vi, all n-mers, i 14n,
- E ? (Vi , Vj ), when Vi represents the n-mer
immdiately upstream of the n-mer represented by
Vj in the genomic sequence
- ki incoming (or outgoing) degree of node i
(Vi) copy number of the n-mer represented by
Vi - During the graph evolution, at each iteration,
one of the following happens deletion (with
probability p0), duplication (with probability
p1) or substitution (with probability q). p0 p1
q 1. - For an arbitrary node Vi , the probabilities of
one of the above events happens is as follows
B. DuplicationWith probability p1
C. Substitution With probability q
43Model Fitting
44Model Fitted Parameter
- The substitution rate, q, increases with the
sizes of mers. - The ratio between duplication and deletion rate,
p1/p0, increases with sizes of mers. - The substitution rate, q, tends to decrease when
the genome sizes are larger. Especially, q is
much smaller in eukaryotic genomes than in
prokaryotic genomes.
45J.B.S. Haldane
- If I were compelled to give my own appreciation
of the evolutionary process, I should say this
In the first place it is very beautiful. In that
beauty, there is an element of tragedyIn an
evolutionary line rising from simplicity to
complexity, then often falling back to an
apparently primitive condition before its end, we
perceive an artistic unity - To me at least the beauty of evolution is far
more striking than its purpose. - J.B.S. Haldane, The Causes of Evolution. 1932.
46Human Cancer Genome
47Cancer
48A Challenge
- At present, description of a recently diagnosed
tumor in terms of its underlying genetic lesions
remains a distant prospect. Nonetheless, we look
ahead 10 or 20 years to the time when the
diagnosis of all somatically acquired lesions
present in a tumor cell genome will become a
routine procedure. - Douglas Hanahan and Robert Weinberg
- Cell, Vol. 100, 57-70, 7 Jan 2000
49Karyotyping
50CGHComparative Genomic Hybridization.
- Equal amounts of biotin-labeled tumor DNA and
digoxigenin-labeled normal reference DNA are
hybridized to normal metaphase chromosomes - The tumor DNA is visualized with fluorescein and
the normal DNA with rhodamine - The signal intensities of the different
fluorochromes are quantitated along the single
chromosomes - The over-and underrepresented DNA segments are
quantified by computation of tumor/normal ratio
images and average ratio profiles
Amplification
Deletion
51CGH Comparative Genomic Hybridization.
52Microarray Analysis of Cancer Genome
- Representations are reproducible samplings of DNA
populations in which the resulting DNA has a new
format and reduced complexity. - We array probes derived from low complexity
representations of the normal genome - We measure differences in gene copy number
between samples ratiometrically - Since representations have a lower nucleotide
complexity than total genomic DNA, we obtain a
stronger specific hybridization signal relative
to non-specific and noise
53Copy Number Fluctuation
A1
B1
C1
A2
B2
C2
A3
B3
C3
54Measuring gene copy number differences between
complex genomes
- Compare the genomes of diseased and normal
samples - Error Control
- The use of representations augmenting microarrays
- Representations reproducibly sample the genome
thereby reducing its complexity. This increases
the signal-to-noise ratio and improves
sensitivity - Statistical Modeling the sources of Noise
- Bayesian Analysis
55Nattering Nabobs of Negativism
- Some scientists are concerned about the cost and
the possibility that a project of this scale
could take money away from smaller ones - Craig Venter, who led a private project to
determine the human DNA blueprint in competition
with the human genome project, said it would make
more sense to look at specific families of genes
known to be involved in cancer. - Lee Hood, president of the Institute for Systems
Biology, has called the premise of the Cancer
Genome Project naïve, suggesting that
signal-to-noise issues its researchers are likely
to encounter will be absolutely enormous.
56Challenges
- ArrayCGH data is noisy!
- Better computational biology algorithms
- Better statistical modelingIn some technologies,
the noise is systematic (e.g., affy SNP-chips) - Better bio-technologies (GRIN Genomics,
Robotics, Informatics, Nanotechnology) - No efficient technology for epigenomics,
translocations or de novo mutations. - Algorithms for multi-locus association studies
- Systems view of cancer by integrating data from
multiple sources - Genomic, Epigenomic, Transcriptomic, Metabolomic
Proteomic. - Regulatory, Metabolic and Signaling pathways
57Mishras Mystical 3Ms
- Rapid and accurate solutions
- Bioinformatic, statistical, systems, and
computational approaches. - Approaches that are scalable, agnostic to
technologies, and widely applicable - Promises, challenges and obstacles
Measure
Mine
Model
58Discussions
59Answer to Cancer
- If I know the answer I'll tell you the answer,
and if I don't, I'll just respond, cleverly. - US Secretary of Defense, Mr. Donald Rumsfeld.
60To be continued